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DBackground: We examined the influence of multiple valve-related parameters on the onset and incidence of
valve degeneration in aortic bioprostheses through detailed echocardiographic follow-up.
Methods: In 648 patients (mean age, 73.8  4.9 years) receiving an aortic valve bioprosthesis, long-term clin-
ical (mean, 7.5  3.2 years) and echocardiographic (mean, 6.5  3.4 years) follow-up were performed. The
occurrence of signs of structural valve degeneration (stenosis type and regurgitation type) was studied through
multivariate analysis, including tissue origin, design and label size of the prosthesis, effective orifice area index
(EOAi), patient-prosthesis mismatch (PPM; EOAi<0.85 cm2/m2), and antimineralization treatment.
Results: Structural valve degeneration (SVD) was diagnosed in 12.6% of patients. In 7.6%, it was of the
stenosis type (S-SVD); in 5%, it was the regurgitation type (R-SVD). The absence of antimineralization treat-
ment is an independent predictor of SVD, S-SVD, and R-SVD. Patient-prosthesis mismatch is an independent
predictor of SVD and S-SVD, but not of R-SVD. Patients receiving a nontreated valve show a freedom of SVD at
10 years follow-up of 70.1 4.3% versus 90.9 3.6% in patients receiving a treated valve (P<.0001). Patients
having PPM and receiving a nontreated valve show a freedom of SVD at 10 years of follow-up of only 59.8 
7.0% versus 88.7  3.6% in patients also having PPM but receiving a treated valve (P<.0001). In patients not
having PPM, the corresponding values were 78.0 4.3% and 92.7 3.4% for nontreated versus treated valves
respectively (P ¼ .01).
Conclusions: Antimineralization treatment of bioprosthetic heart valves is effective and reduces the incidence
of SVD significantly. Because valve type and size are determined at the moment of implantation, the surgeon
carries an important responsibility in protecting the patient from valve degeneration. (J Thorac Cardiovasc
Surg 2014;147:1219-24)In a previous study, we showed that patient-prosthesis
mismatch (PPM) is associated with an increased incidence
of structural valve degeneration (SVD) in patients receiving
a bioprosthetic aortic valve.1 Our report on this issuewas re-
viewed critically and it was concluded that we presented
compelling evidence that the insertion of a bioprosthesis
that is too small in relation to body size is harmful in the
long term.2-5 However, Yacoub and El-Hamamsy5 pointed
out in their comment that also other forms of interactions
between host and valve, apart from PPM, can cause struc-
tural and functional changes. To study the interrelationship
between PPM and these confounding factors in the develop-
ment of SVD, it is necessary to consider a multivariateardiac Surgery, Department of Cardiovascular Diseases, Katholieke Universi-
euven, Leuven, Belgium.
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The Journal of Thoracic and Carapproach that has to include not only patient-related factors,
but also valve-related factors such as valve design (stented
or stentless), origin of the tissue used to construct the valve
(porcine aortic valve or bovine pericardium), and anticalci-
fication treatment of the valve. For example, novel strate-
gies to mitigate valve calcification could play a role.
Indeed, we know from clinical and experimental work
that besides the age of the recipient, the design-related
stress distribution on the device, the origin of the tissue
and the type of agent used to cross-link this tissue, and
the anticalcification treatment used during the preparation
of the device are fundamental factors in determining the cal-
cification potential of bioprosthetic valves.6 To deal with
the variety of these possible factors influencing valve dura-
bility, we performed a clinical study that included 8 types of
bioprostheses: stented as well as stentless valve types, por-
cine and pericardial valves, and valves treated with antimi-
neralization technology or not.METHODS
Patient Population
A group of 648 patients (mean age, 73.8  4.9 years; 52% males)
underwent aortic valve replacement using a bioprosthetic valve. Theirdiovascular Surgery c Volume 147, Number 4 1219
Abbreviations and Acronyms
EOA ¼ effective orifice area
EOAi ¼ effective orifice area index
PPM ¼ patient-prosthesis mismatch
R-SVD ¼ regurgitation-type structural valve
degeneration
S-SVD ¼ stenotic-type structural valve
degeneration
SVD ¼ structural valve degeneration
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Dmean body surface area was 1.78 0.19 m2. The majority (94%, n¼ 609)
had aortic valve stenosis combined eventually with regurgitation, and 6%
(n ¼ 39) had regurgitation exclusively. The mean ejection fraction was
62%, and 87% (n¼ 564) was in sinus rhythm, 8% (n¼ 52) in atrial fibril-
lation, and 5% (n¼ 32) had pacemaker rhythm. Five percent of the patients
(n ¼ 32) were in New York Heart Association functional class I, 48%
(n ¼ 311) in class II, 40% (n ¼ 259) in class III, and 7% (n ¼ 46) in class
IV. Forty-nine percent of patients (n¼ 312) received concomitant coronary
bypass grafting.
Prosthetic Valve Characteristics
Specific valve models, design, tissue origin, and tissue treatment are
listed in Table 1, together with patient-related variables grouped per valve
type. Two types of valve design were used: stented (n ¼ 449 or 69% of
cases) or stentless (n ¼ 199 or 31%) bioprostheses. Median label size
was 23 mm (range, 19-29 mm), for stentless valves it was 25 mm (range,
19-29 mm), and for stented valves it was 23 mm (range, 19-29 mm).
Two types of biologic material were used: porcine aortic valves (n ¼ 396
or 61%) and bovine pericardial tissue (n ¼ 252 or 39%). The valves
were either treated with an antimineralization treatment (n ¼ 377 or
58%) or had no treatment (n ¼ 271 or 42%).
Patient-Prosthesis Mismatch
Patient-prosthesis mismatch was calculated using the patients’ body
surface area and the values of the corresponding reference effective orifice
area (EOA) of the used valves according to literature data.7-9 PPM was
defined as an EOA index (EOAi)<0.85 cm2/m2.
Follow-up and Structural Valve Deterioration
Clinical and echocardiographic follow-up was performed at hospital
discharge and thereafter periodically by the referring cardiologist. Sur-
vival, reoperation, cerebrovascular accidents, bleeding complications, anti-
coagulation therapy, New York Heart Association class, and cardiac
rhythm were recorded. In this study, echocardiographic findings during
follow-up were used to detect early signs of SVD.1 Two types of SVD
were distinguished: a stenotic type (S-SVD) or a regurgitation type
(R-SVD). For every valve model used, the mean value of the peak pressure
gradient across the valve at discharge was determined for the patient pop-
ulation receiving this valve model. A cutoff value was then calculated by
adding 1 standard deviation to the obtainedmean value of the peak pressure
gradient of this specific valve model. When, during the follow-up, persist-
ing values of the peak pressure gradient above this cutoff occurred, the di-
agnosis of S-SVDwas made. In none of the patients, regardless of the valve
model, was a valvular regurgitation score>1/4 found at discharge. There-
fore, a patient developing a valvular regurgitation of a degree>1/4 during
follow-up, was diagnosed as having R-SVD. Patients developing a combi-
nation of valve stenosis and regurgitation were classified as having S-SVD.
For the analysis of SVD, we obviously excluded the in-hospital deaths
(n ¼ 37) and patients with insufficient echocardiographic follow-up1220 The Journal of Thoracic and Cardiovascular Sur(n ¼ 31), resulting in a population of 580 patients with long-term clinical
and echocardiographic follow-up.
Statistical Analysis
For the formulation of valve-related complications, standard guidelines
and definitions of terms were used according to recently published recom-
mendations.10 Univariate testing for comparisons between groups was per-
formed using nonparametric tests (Kruskal-Wallis, Mann-Whitney, and
Wilcoxon). Overall survival and freedom from SVD were visualized using
Kaplan-Meier curves. Log-rank testing was used for comparison between 2
groups. Further analysis included standard single predictor and multivari-
able (P<.1 threshold to enter the model) Cox proportional hazards models.
The following variables were analyzed: (1) patient-related variables such
as age, gender, need for concomitant bypass grafting, treated diabetes mel-
litus, hypercholesterolemia, arterial hypertension, obesity (body mass
index>30), statin use, and presence of metabolic syndrome (at least 3 of
the previous 5 factors present); and (2) valve-related variables, including
labeled size, type, design (stented or stentless), tissue origin (porcine or
pericardial), presence of anticalcification treatment, EOAi, and PPM.
P<.05 was considered statistically significant for the study.RESULTS
Follow-up
Follow-up was 98% complete (12 patients were lost to
follow-up). The median follow-up period was 7.7 years
(mean, 7.5 3.2 years), with a maximum of 15.6 years. Im-
plant and follow-up periods for the different valve models
are given in Table 1. Considering length of follow-up, there
are no significant differences between the subgroups
(P ¼ .15). Echocardiography was performed in 95.3% of
the hospital survivors. In total, 2990 echo reports were col-
lected (mean, 4.6 echo reports per patient). In 61% of the
patients, the last echocardiography was recorded within
the last year of clinical follow-up, and in 79% was within
the last 3 years. We reached a median echocardiographic
follow-up of 7.0 years (mean, 6.5  3.4 years).Clinical Outcome
Hospital mortality was 5.2%. Overall survival at 10 years
was 48.3 4.1% and freedom from cardiac death was 73.7
 5.4%. At 10 years, freedom from hospital readmission
for cardiac reasons was 54.6 3.9%, freedom from throm-
boembolic events and/or major anticoagulation-related
bleeding was 95.8  1.7%, and freedom from reoperation
was 94.4  1.3%. Twenty patients developed acute bacte-
rial endocarditis during the postoperative follow-up. These
patients were excluded from further analysis of SVD.Patient-Prosthesis Mismatch
The overall incidence of PPMwas 53%. The incidence in
each valve type is listed in Table 1. Forty-seven percent of
the patients had an EOAi >0.85 cm2/m2, 49% had an
EOAi between 0.85 cm2/m2 and 0.65 cm2/m2, and 4%
had and EOAi<0.65 cm2/m2. For further analysis, we con-
sidered a value<0.85 cm2/m2 as PPM (53%). Stentless
valves had significantly less PPM (44 patients out of 199,gery c April 2014
Flameng et al Acquired Cardiovascular Diseaseor 22%) than stented valves (301 out of 449, or 67%;
P< .0001). Patients having PPM had significantly higher
peak gradients at discharge than patients not having PPM
(31.1  11.7 mm Hg vs 21.3  8.5 mm Hg, P<.0001).A
C
DStructural Valve Degeneration
The diagnosis of SVD was made in 73 patients (12.6%).
Forty-four patients had a stenotic valve (S-SVD; 7.6%) and
29 patients had an incompetent valve (R-SVD; 5.0%).
Based on these echocardiographic criteria, freedom from
SVD was substantially lower than that of reoperation
(Figure 1). At 10 years, freedom from SVD was 81.0 
2.4% whereas freedom from reoperation was 94.4 
1.3%. Stringent echocardiographic follow-up leads to
(early) detection of SVD in a phase when reoperation is
not required (yet).
In the univariate Cox analysis toward SVD and toward the
2 subtypes (S-SVD and R-SVD), the following variables re-
vealed a P value<.1: (1) labeled valve size, EOAi, absence
of anticalcification treatment, and presence of PPM for SVD
and for S-SVD; and (2) labeled valve size, tissue origin, and
absence of anticalcification treatment for R-SVD. These
variables were inserted into the multivariable Cox models
(Table 2). None of the patient-related variables proved to
be significantly related to any of the SVD forms.
The multivariable Cox analysis revealed that absence of
anticalcification treatment is an independent predictor of
SVD, S-SVD, and R-SVD. Patient-prosthesis mismatch is
an independent predictor of SVD and S-SVD, but not of
R-SVD. Table 2 summarizes all P values from the single-
predictor analysis, together with the hazard ratios resulting
from the multivariable Cox analysis.
Patients receiving a nontreated valve show a freedom
from SVD (all forms) at 10 years of follow-up of 70.1 
4.3% versus 90.9  3.6% in patients receiving a treated
valve (Figure 2,A;P<.0001). Valve treatment induces a sig-
nificant delay of both S-SVD (Figure 2, B) and of R-SVD
(Figure 2, C). Stenotic-type SVD starts to occur much ear-
lier (at about 3-5 years) than R-SVD, which starts late (at
about 9-10 years), but progresses quickly in the group
having a nontreated valve (Figure 2, B and C). Figure 3 il-
lustrates the effect of PPM on S-SVD, as we have demon-
strated previously.1Additive Effect of Anticalcification Treatment and
PPM
The interaction between PPM and anticalcification treat-
ment on the incidence of SVD is depicted in Figure 4. Pa-
tients having PPM and receiving a nontreated valve show
a freedom of SVD at 10 years of follow-up of only 59.8
 7.0% versus 88.7 3.6% in patients having PPM but re-
ceiving a treated valve (P<.0001). In patients not having
PPM, the corresponding values were 78.0  4.3% andThe Journal of Thoracic and Car92.7  3.4% for nontreated versus treated valves, respec-
tively (P<.01).
DISCUSSION
The efficacy of antimineralization treatments of biopros-
thetic heart valves has never been proved in a clinical set-
ting. Although several of these antimineralization
treatments are actually applied to clinically available tissue
valves, clinical trials to show their efficacy were never
required by health care authorities. The only evidence of ef-
ficacy is provided by experimental studies, including the ac-
celerated calcification models in sheep.6,11-13 From clinical
work, we know that the age of the recipient will determine
the incidence of prosthetic valve degeneration.14,15
Experimental work was needed to show that factors such
as the design-related stress distribution on the device, the
origin of the tissue, the type of agent used to cross-link
this tissue, and, last, the anticalcification treatment used
during the preparation of the devices are all factors deter-
mining the calcification potential of these bioprosthetic
valves.6,11-13
In this study, we included the following valves as non-
treated prostheses: the Pericarbon and the Mitroflow (both
Sorin, Saluggia, Italy) valve as stented bovine pericardial
valves, the Labcor valve (Sulzer Carbomedics, Austin,
Tex) as a stented porcine valve, and the Toronto SPV (St
Jude Medical, St Paul, Minn) and the Prima (Edwards,
Irvine, Calif) valves as stentless porcine prostheses. As
treated valves, we included the Perimount valve (Edwards)
as a stented pericardial valve, the Mosaic valve (Medtronic,
Minneapolis, Minn) as a stented porcine valve, and the
Freestyle valve (Medtronic) as a stentless porcine valve.
This means that we accepted alpha-oleic acid as a treatment
in the Mosaic and the Freestyle valves, and Tween-80 as
a treatment in the Perimount valve.6
Our current data suggest that antimineralization treatment
of bioprosthetic heart valves is effective and reduces the onset
and incidence of both forms of SVD significantly. Remark-
able is that these treatments not only prevent or at least post-
pone prosthetic valve stenosis, but also can prevent valve
regurgitation, most likely caused by cusp rupture. As Car-
pentier2 highlighted in his editorial comment on our previous
work, the originality of our previous study1 relating PPM to
SVD was in the distinction between 2 simple categories of
valve structural deterioration (ie, S-SVD and R-SVD) and
their relation to PPM. Indeed, not all bioprostheses showing
SVD exhibit stenosis and calcification. Some valves show
only rupture of the cusps, whereas others show the combina-
tion of leaflet calcification and rupture.16,17 Cusp ruptures
were often associated with fatigue of the material; but, on
the other hand, tears in the leaflets were also associated
with micro- or macroscopic calcification of the tissue,
which are possible causes of cusp ruptures.18,19 We classify
bioprosthetic valves showing increasing pressure gradientsdiovascular Surgery c Volume 147, Number 4 1221
TABLE 1. Descriptive data of the valve types included in the study
Valve Type n Implant period Design Tissue origin Treatment Incidence PPM Clinical FU (y)
Mosaic 148 1997-2003 Stented Porcine Treated 67.6% 7.1  2.9
Pericarbon 48 1993-1995 Stented Pericardial Untreated 70.8% 7.3  4.3
Perimount 165 1995-2004 Stented Pericardial Treated 61.8% 7.7  2.0
Labcor 49 2000-2003 Stented Porcine Untreated 85.7% 6.0  2.6
Mitroflow 39 2000-2004 Stented Pericardial Untreated 58.9% 6.1  2.9
Toronto SPV 85 1995-2002 Stentless Porcine Untreated 23.5% 8.7  2.9
Freestyle 64 1996-2005 Stentless Porcine Treated 25.0% 7.2  3.1
Prima 50 1991-1993 Stentless Porcine Untreated 18% 9.4  3.7
PPM, Patient-prosthesis mismatch; FU, follow-up (mean standard deviation);CABG, concomitant coronary bypass grafting; AHT, hypertension;DM, treated diabetes mellitus;
Chol, hypercholesterolemia;Obes, obesity (bodymass index>30); Stat, statin use;MS, presence of metabolic syndrome (at least 3 of the previous 5 factors present); SPV, stentless
porcine valve.
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Dacross the valve in combination with regurgitation as S-SVD.
Valves demonstrating only valvular regurgitation are
classified as R-SVD. To make this distinction, complete
echocardiographic follow-up data, including pressure gradi-
ents across the valve, description of leaflet calcification, and
semiquantitative indications of regurgitation, become man-
datory to classify valve failure. It is clear that, only through
stringent echocardiographic follow-up, an early detection of
SVD is possible during a phase when reoperation is not
required (yet). Too many clinical reports studying SVD use
the (late) event of reoperation as the moment of (end-stage)
SVD diagnosis.
The concept of PPM implies, as a main hemodynamic
consequence, the generation of higher than expected gradi-
ents through normally functioning prosthetic valves.20 The
incidence of moderate and severe PPM can vary substan-
tially within published series, depending on valve types
studied and used EOA reference values.21 High-pressure
gradients at the outflow of the left ventricle can explain
the association of PPM with less regression of left ventric-
ular hypertrophy, more cardiac events, and lower survival,FIGURE 1. Freedom from reoperation (solid line) and SVD (dashed line).
It is clear that stringent echocardiographic follow-up leads to detection of
SVD in a phase when reoperation is not required (yet). Numbers at risk
are shown at 4, 8, and 12 years. SVD, Structural valve degeneration;
Redo, reoperation.
1222 The Journal of Thoracic and Cardiovascular Suras shown by Pibarot and Dumesnil.7 However, such a distur-
bance of hemodynamic flow patterns might also have an in-
fluence on the structural integrity of the prosthetic valve
tissue and may result in the calcifying stenosis of the pros-
thesis that we find in our patients having PPM. We showed
clearly that PPM is an independent predictor of S-SVD but
not of R-SVD. On the other hand, we also showed that ab-
sence of treatment of bioprosthetic valves predicts a greater
incidence of S-SVD and R-SVD. This finding suggests that
alpha-oleic acid and Tween-80 treatments protect not only
against leaflet calcification, but also against leaflet matrix
instability and rupture.
The clinical consequence of our findings is clear: Besides
the prevention of PPM, the use of nontreated bioprosthetic
heart valves should be avoided. Because valve type and size
are determined at the moment of implantation, the surgeon
carries an important responsibility in protecting the patient
from valve degeneration.
Study Limitations
Structural valve degeneration is a nonfatal event. Its diag-
nosis and the time of detection depend highly on the
frequency and completeness of echocardiographic follow-
up within the patient cohort. In the analysis of these events,TABLE 2. Statistical analysis
Factor SVD
Stenotic-type
SVD
Regurgitation-type
SVD
Tissue origin —* —* NSy
No treatment 2.97 (2.32-3.82) 4.44 (3.16-6.23) 3.16 (2.01-4.95)
EOAi NSy NSy —*
PPM 1.95 (1.52-2.51) 2.69 (1.82-3.97) —*
Size NSy NSy NSy
Multivariable analysis of SVD (all forms), stenotic-type and regurgitation-type SVD.
Analyzed factors included labeled valve size, EOAi, absence of anticalcification
treatment, and presence of PPM for SVD and for stenotic-type SVD; and labeled
valve size, tissue origin, and absence of anticalcification treatment for
regurgitation-type SVD. If the factor remained significant in the multivariable setting,
the resulting hazard ratio is shown with its 95% confidence interval. SVD, Structural
valve degeneration; NS, not significant; EOAi, effective orifice area index; PPM,
patient-prosthesis mismatch. *The factor was not analyzed within the multivariable
model given its nonsignificant univariate P value. yThe factor was no longer signifi-
cant in the multivariable model.
gery c April 2014
Echo FU (y) Male CABG AHT DM Chol Obes Stat MS
6.0  3.4 78 (53%) 82 (55%) 109 (74%) 21 (14%) 40 (27%) 30 (20%) 25 (17%) 16 (11%)
5.5  3.8 22 (46%) 41 (83%) 32 (68%) 7 (15%) 7 (15%) 3 (6%) 3 (6%) 3 (6%)
5.6  3.3 84 (51%) 72 (44%) 121 (74%) 24 (15%) 63 (39%) 24 (15%) 35 (21%) 18 (11%)
5.5  2.7 28 (57%) 27 (53%) 21 (43%) 5 (10%) 19 (39%) 6 (12%) 13 (27%) 3 (6%)
6.0  2.9 21 (54%) 20 (51%) 20 (51%) 5 (13%) 9 (23%) 3 (8%) 7 (18%) 1 (3%)
7.9  3.1 43 (51%) 45 (52%) 38 (45%) 11 (13%) 39 (46%) 11 (13%) 22 (26%) 9 (11%)
7.0  3.6 36 (56%) 25 (39%) 44 (69%) 14 (22%) 16 (25%) 14 (22%) 9 (14%) 9 (14%)
7.3  3.7 25 (50%) 0 (0%) 30 (60%) 4 (8%) 9 (18%) 4 (8%) 1 (2%) 1 (2%)
TABLE 1. Continued
Flameng et al Acquired Cardiovascular Disease
Dideally an interval-censored technique is used, with the time
interval between the last echocardiographic follow-up
demonstrating normal valve function and the first echocar-
diographic follow-up demonstrating SVD. In 2 previous
studies, we did so and used the poor man’s data augmenta-
tion multiple imputation method for interval censored data,
according to Pan.1,22,23 In addition, the nonparametricFIGURE 2. A, Freedom from SVD (all forms) in patients with a treated or a no
patients with a treated or a nontreated valve (log-rank P<.0001). C, Freedom f
(log-rank P ¼ .0009). Numbers at risk are shown at 4, 8 and 12 years.
The Journal of Thoracic and CarTurnbull estimate was used instead of Kaplan-Meier curves
to create a graphic representation of the time to SVD. Post
factum, however, no difference was shown between the out-
come of these models in comparison with the regular Cox
analysis and Kaplan-Meier estimates, which was most
likely a result of the fact that our echocardiographic data
were quite extensive and complete. In this series, evenntreated valve (log-rank P<.0001). B, Freedom from stenotic-type SVD in
rom regurgitation-type SVD in patients with a treated or a nontreated valve
diovascular Surgery c Volume 147, Number 4 1223
A
C
FIGURE 3. Freedom from stenotic-type SVD in patients with or without
PPM (log-rank P ¼ .003). Numbers at risk are shown at 4, 8, and 12 years.
PPM, Patient-prosthesis mismatch.
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Dmore echocardiographic data were collected, which led us
to refrain from these ‘‘complex’’ and less familiar models
and to use regular statistical methods. Throughout this
study, peak gradients were used for the SVD diagnosis, be-
cause the incompleteness of mean transvalvular gradients
and EOAi’s inhibited their use in the analysis. We were un-
able to reveal an effect of patient-related variables on SVD,
potentially because of the older mean age of our population
and the relative low number of SVD events, compromising
the power of the analysis. The low event rate also makes itFIGURE 4. Additive effect of valve anticalcification treatment and PPM
on freedom from SVD (all forms). Black curves represent treated valves;
red curves represent untreated valves. Patients with PPM are represented
with dashed lines. Patients having PPM and receiving an untreated valve
show a freedom from SVD at 10 years of follow-up of only 59.8 
7.0% versus 88.7  3.6% in patients having PPM but receiving a treated
valve (P<.0001). In patients not having PPM, the corresponding values
were 78.0  4.3% and 92.7  3.4% for nontreated versus treated valves,
respectively (P<.01). Numbers at risk are shown at 4, 8, and 12 years.
PPM, Patient-prosthesis mismatch.
1224 The Journal of Thoracic and Cardiovascular Surimpossible to discriminate the effect of different types of
antimineralization agents.References
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